Association of metabolic syndrome and blood pressure nondipping profile in untreated hypertension

American Journal of Hypertension

Volumn 22, Issue 3, 2009, Pages 307-313

  Hermida, Ramón C ^a   Chayán, Luisa ^b,c   Ayala, Diana E ^a   Mojón, Artemio ^a   Domínguez, María J ^b   Fontao, María J ^a   Soler, Rita ^a   Alonso, Ignacio ^a   Fernández, José R ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Urgencias Sanitarias 061 Galicia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; URIC ACID;

ACTIMETRY; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SEDIMENTATION RATE;

ADULT; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; CREATINE; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOGEN; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; SMOKING; URIC ACID;

EID: 60549113687     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.358     Document Type: Article

References (36)

1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 1998; 47:1643-1649.
2. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999; 245:163-174.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Frauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Hearty Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
4. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Leonetti G, Magrini F, Zanchetti A. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22:1991-1998.
5. Lind L, Andersson PE, Andren B, Hanni A, Lithell HO. Left ventricular hyperthrophy in hypertension is associated with insulin-resistance metabolic syndrome. J Hypertens 1995; 13:433-438.
6. Palaniappan L, Carnethon M, Fortman SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16:952-958.
7. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, Vaudo G, Mannarino E. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 2006; 47:881-886.
8. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
9. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107:391-397.
10. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactice protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
11. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109:42-46.
12. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822.
13. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
14. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, for the Systolic Hypertension in Europe (Syst-Eur) trial investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282:539-546.
15. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20:2183-2189.
16. Hermida RC, Ayala DE, Calvo C, Covelo M, Mojón A, Fernández JR, Fontao MJ, Soler R, López JE. Biological markers of the day/night blood pressure ratio determined by ambulatory monitoring in hypertensive patients. Chronobiol Int 2005; 22:1220-1221.
17. Foss CH, Vestbo E, Froland A, Gjessing HJ, Mogensen CE, Damsgaard EM. Normal blood pressure and preserved diurnal variation in offspring of type 2 diabetic patients characterized by features of the metabolic syndrome: the Fredericia Study. Diabetes Care 2000; 23:283-289.
18. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Sala C, Magrini F, Zanchetti A. Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome? Blood Press 2004; 13:230-235.
19. Cuspidi C, Meani S, Valerio C, Catini E, Fusi V, Sala C, Zanchetti A. Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension. Blood Press Monit 2005; 10:175-180.
20. Tartan Z, Uyarel H, Kasikcioglu H, Alper AT, Ozay B, Bilsen T, Gul M, Ozturk R, Cam N. Metabolic syndrome as a predictor of non-dipping hypertension. Tohoku J Exp Med 2006; 210:57-66.
21. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano FQ, Grassi G, Zanchetti A, Sega R. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40-47.
22. Bastos JM, Bertoquini S, Polonia J. Relationship of circadian blood pressure and morning blood pressure surge with the severity of metabolic syndrome in newly diagnosed hypertensives. Rev Port Cardiol 2007; 26:731-741.
23. Vyssoulis GP, Karpanou EA, Kyvelou SMG, Adamopoulos DN, Deligeorgis AD, Spanos PG, Pietri PG, Cokkinos DF, Stefanadis CI. Nocturnal blood pressure fall and metabolic syndrome score in hypertensive patients. Blood Press Monit 2007; 12:351-356.
24. Hermida RC, Calvo C, Ayala DE, Fernández JR, Ruilope LM, López JE. Evaluation of the extent and duration of the "ABPM effect" in hypertensive patients. J Am Coll Cardiol 2002; 40:710-717.
25. Hermida RC, Ayala DE, Fernandez JR, Mojón A, Calvo C. Influence of measurement duration and frequency on ambulatory blood pressure monitoring. Rev Esp Cardiol 2007; 60:131-138.
26. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. 2007 guidelines for the management of arterial hypertension.The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
27. Staessen J, Fagard R, Lijnen P, Thijs L, Vaa Hoof R, Amery A. Ambulatory blood pressure monitoring in clinical trials. J Hypertens 1991;9(Suppl 1):S13-S19.
28. Asmar R, Vol S, Brisac AM, Tichet J, Topouchian J. Reference values for clinic pulse pressure in a nonselected population. Am J Hypertens 2001; 14:415-418.
29. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32:983-988.
30. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161.
31. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 2005; 45:240-245.
32. Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension 2005; 45:602-607.
33. Mulè G, Nardi E, Cottone S, Cusimano P, Incalcaterra F, Palermo A, Giandalia ME, Mezzatesta G, Andronico G, Cerasola G. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am J Hypertens 2007; 20:197-203.
34. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JI, Ducimetiere P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415.
35. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103:2579-2584.
36. Mochizuki Y, Okutani M, Donfeng Y, Iwasaki H, Takusagawa M, Kohno I, Mochizuki S, Umetani K, Ishii H, Ijiri H, Komori S, Tamura K. Limited reproducibility of circadian variation in blood pressure dippers and nondippers. Am J Hypertens 1998; 11:403-409.